<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 03, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00006456</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000068151</org_study_id>
    <secondary_id>P30CA016059</secondary_id>
    <secondary_id>MCV-MCC-9812-2C</secondary_id>
    <secondary_id>NCI-V00-1612</secondary_id>
    <nct_id>NCT00006456</nct_id>
  </id_info>
  <brief_title>Stereotactic Radiosurgery in Treating Patients With Liver Metastases, Lung Metastases, or Other Advanced Solid Tumors</brief_title>
  <official_title>Fractionated Stereotactic Body Radiosurgery for Extracranial Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Virginia Commonwealth University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Virginia Commonwealth University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Stereotactic radiosurgery delivers x-rays directly to the tumor and may cause less&#xD;
      damage to normal tissue.&#xD;
&#xD;
      PURPOSE: Phase II trial to study the effectiveness of stereotactic radiosurgery in treating&#xD;
      patients who have liver metastases, lung metastases, or other advanced solid tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the feasibility of fractionated stereotactic body radiosurgery in patients&#xD;
           with advanced extracranial tumors.&#xD;
&#xD;
        -  Assess the toxicities of this treatment regimen in these patients.&#xD;
&#xD;
        -  Determine tumor response and cause of death in these patients treated with this regimen.&#xD;
&#xD;
      OUTLINE: Patients receive fractionated stereotactic body radiosurgery over 30 minutes for&#xD;
      5-10 days for a total of 3 treatments.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 10-25 patients will be accrued within 2-3 years.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1999</start_date>
  <completion_date type="Actual">November 2004</completion_date>
  <primary_completion_date type="Actual">November 2004</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">26</enrollment>
  <condition>Metastatic Cancer</condition>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic radiosurgery</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed malignancy&#xD;
&#xD;
               -  Extracranial recurrent or metastatic disease or primary tumor not predicted to be&#xD;
                  controlled with standard radiotherapy&#xD;
&#xD;
               -  Incurable with any standard therapy&#xD;
&#xD;
          -  No tumors involving critical structures (e.g., mucosal surfaces (bowel or bladder) or&#xD;
             heart)&#xD;
&#xD;
          -  Tumor visible by CT scan&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status:&#xD;
&#xD;
          -  Karnofsky 60-100%&#xD;
&#xD;
        Life expectancy:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic:&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic:&#xD;
&#xD;
          -  Bilirubin less than 2.0 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT less than 5 times ULN&#xD;
&#xD;
        Renal:&#xD;
&#xD;
          -  Creatinine less than 2.0 mg/dL&#xD;
&#xD;
        Pulmonary:&#xD;
&#xD;
          -  FEV1 greater than 0.75 L&#xD;
&#xD;
        Other:&#xD;
&#xD;
          -  No unsuitable size or geometric proportion that would preclude stereotactic&#xD;
             immobilization&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy:&#xD;
&#xD;
          -  At least 14 days since prior anticancer biologic therapy and recovered&#xD;
&#xD;
        Chemotherapy:&#xD;
&#xD;
          -  At least 14 days since prior anticancer chemotherapy and recovered&#xD;
&#xD;
        Endocrine therapy:&#xD;
&#xD;
          -  At least 14 days since prior anticancer endocrine therapy and recovered&#xD;
&#xD;
        Radiotherapy:&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 14 days since prior anticancer radiotherapy and recovered&#xD;
&#xD;
        Surgery:&#xD;
&#xD;
          -  Not specified&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Danny Y. Song, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Massey Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massey Cancer Center</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23298-0058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <study_first_submitted>November 6, 2000</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>February 23, 2010</last_update_submitted>
  <last_update_submitted_qc>February 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 24, 2010</last_update_posted>
  <responsible_party>
    <name_title>Danny Song, MD</name_title>
    <organization>Virginia Commonwealth University/Massey Cancer Center</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <keyword>lung metastases</keyword>
  <keyword>liver metastases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

